GBMA welcomes the ‘a’ flagging of biosimilar infliximab

A on tag
The Generic and Biosimilar Medicines Association has welcomes the recommendation by the PBAC to list biosimilar infliximab (Inflectra) on the PBS and to recommend the marking as equivalent, also known as “a” flagging, of Inflectra with the reference product, Remicade. “PBS savings and improved patient access can only be realised if the use of biosimilars

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous There’s still time to register for PA2015!
Next Have you completed your Nuromol product training on RB HealthHub yet?